Carregant...
Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development: a review
Programmed death-1/programmed death ligand-1 (PD-1/PD-L1) based immunotherapy is a revolutionary cancer therapy with great clinical success. The majority of clinically used PD-1/PD-L1 inhibitors are monoclonal antibodies but their applications are limited due to their poor oral bioavailability and i...
Guardat en:
| Publicat a: | Cancer Cell Int |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8077906/ https://ncbi.nlm.nih.gov/pubmed/33906641 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12935-021-01946-4 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|